GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » EPS without NRI

MyMD Pharmaceuticals (MyMD Pharmaceuticals) EPS without NRI : $-13.74 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals EPS without NRI?

MyMD Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-1.86. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.74.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for MyMD Pharmaceuticals's EPS without NRI or its related term are showing as below:

MYMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.4   Med: -19.4   Max: -19.4
Current: -19.4

During the past 4 years, MyMD Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -19.40% per year. The lowest was -19.40% per year. And the median was -19.40% per year.

MYMD's 3-Year EPS without NRI Growth Rate is ranked worse than
75.1% of 1293 companies
in the Biotechnology industry
Industry Median: 4.9 vs MYMD: -19.40

MyMD Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-5.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.57.

MyMD Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-5.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.57.


MyMD Pharmaceuticals EPS without NRI Historical Data

The historical data trend for MyMD Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyMD Pharmaceuticals EPS without NRI Chart

MyMD Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS without NRI
-7.67 -24.57 -11.74 -13.05

MyMD Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.41 -4.37 -3.37 -4.15 -1.86

Competitive Comparison of MyMD Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, MyMD Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MyMD Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where MyMD Pharmaceuticals's PE Ratio without NRI falls into.



MyMD Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyMD Pharmaceuticals  (NAS:MYMD) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


MyMD Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.
Executives
Paul Rivard officer: EVP of Operations, GC C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams 10 percent owner 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin officer: Chief Scientific Officer C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne director C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle director POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr director, officer: President, Chief Med. Officer C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes officer: Interim CFO 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Headlines

From GuruFocus

MyMD Announces $15 Million Offering with Existing Investors

By Business Wire Business Wire 02-21-2023